SCHEMBL15070232

SCHEMBL15070232

CC(=O)c1ccc(-c2cc(-c3cccnc3)nn2-c2ccc(Cl)c(Cl)c2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.56
CYP2A6 P11509 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
USP8 P40818 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
RPA1 P27694 4/20 0.43
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10168238 0.91 MKNK1 (0.55) CYP3A4CYP2A6CYP2C9CYP2C19USP8
SCHEMBL15070407 0.90 USP8 (0.44) CYP3A4CYP2A6CYP2C9CYP2C19USP8
SCHEMBL14626195 0.90 MKNK1 (0.43) CYP3A4CYP2A6CYP2C9CYP2C19USP8
SCHEMBL13901964 0.89 USP8 (0.52) CYP3A4CYP2A6CYP2C9CYP2C19USP8
SCHEMBL10168237 0.87 USP8 (0.48) CYP3A4CYP2A6CYP2C9CYP2C19USP8
SCHEMBL13902340 0.84 HDAC3 (0.43) USP8MKNK1MKNK2RPA1NPC1
SCHEMBL13902067 0.84 HPGDS (0.45) USP8MKNK1MKNK2RPA1NPC1
SCHEMBL13902232 0.81 GGT1 (0.47) USP8HDAC3HDAC4HDAC1HDAC7
SCHEMBL13902372 0.81 GGT1 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13902238 0.80 GGT1 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165483-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165483-A1 HETEROARYLS AND USES THEREOF PIK3R5, PIK3R4, PIK3C2B CYP3A4 769/4885CYP2A6 869/4885CYP2C9 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.